PL2303330T5 - Kompozycje farmaceutyczne do leczenia choroby Parkinsona - Google Patents

Kompozycje farmaceutyczne do leczenia choroby Parkinsona

Info

Publication number: PL2303330T5
Authority: PL; Poland
Prior art keywords: parkinson; disease; treatment; pharmaceutical compositions; pharmaceutical
Prior art date: 2008-06-06

Application number

PL09758025T

Other languages

English (en)

Other versions

PL2303330T3 (pl

Inventor

Itschak Lamensdorf

Yoram Sela

Original Assignee

Pharma Two B Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-06

Filing date

2009-06-07

Publication date

2021-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2303330(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-07 Application filed by Pharma Two B Ltd. filed Critical Pharma Two B Ltd.

2018-04-30 Publication of PL2303330T3 publication Critical patent/PL2303330T3/pl

2021-10-25 Publication of PL2303330T5 publication Critical patent/PL2303330T5/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL09758025T 2008-06-06 2009-06-07 Kompozycje farmaceutyczne do leczenia choroby Parkinsona PL2303330T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5932608P	2008-06-06	2008-06-06
PCT/IL2009/000567 WO2009147681A1 (en)	2008-06-06	2009-06-07	Pharmaceutical compositions for treatment of parkinson's disease
EP09758025.2A EP2303330B2 (en)	2008-06-06	2009-06-07	Pharmaceutical compositions for treatment of parkinson's disease

Publications (2)

Publication Number	Publication Date
PL2303330T3 PL2303330T3 (pl)	2018-04-30
PL2303330T5 true PL2303330T5 (pl)	2021-10-25

Family

ID=41051156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09758025T PL2303330T5 (pl)	2008-06-06	2009-06-07	Kompozycje farmaceutyczne do leczenia choroby Parkinsona

Country Status (22)

Country	Link
US (2)	US8969417B2 (pl)
EP (1)	EP2303330B2 (pl)
JP (1)	JP5648216B2 (pl)
KR (1)	KR101613749B1 (pl)
CN (1)	CN102105169B (pl)
AU (1)	AU2009254730B2 (pl)
BR (1)	BRPI0914902B8 (pl)
CA (1)	CA2726833C (pl)
CL (1)	CL2010001358A1 (pl)
CY (1)	CY1119865T1 (pl)
DK (1)	DK2303330T4 (pl)
ES (1)	ES2659394T5 (pl)
HU (1)	HUE037974T2 (pl)
LT (1)	LT2303330T (pl)
MX (1)	MX2010013393A (pl)
NO (1)	NO2303330T3 (pl)
NZ (1)	NZ590291A (pl)
PL (1)	PL2303330T5 (pl)
PT (1)	PT2303330T (pl)
RU (1)	RU2540470C9 (pl)
WO (1)	WO2009147681A1 (pl)
ZA (1)	ZA201100034B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2734632C2 (ru)	2010-02-03	2020-10-21	Фарма Ту Б Лтд.	Составы разагилина с пролонгированным высвобождением и их применение
TW201304822A (zh) *	2010-11-15	2013-02-01	Vectura Ltd	組成物及用途
PL2802319T3 (pl) *	2012-01-12	2018-04-30	Pharma Two B Ltd.	Leczenie choroby Parkinsona preparatem złożonym
US9504657B2 (en) *	2012-01-12	2016-11-29	Pharmatwob Ltd.	Fixed dose combination therapy of Parkinson's disease
WO2013168032A1 (en) *	2012-05-07	2013-11-14	Micro Labs Limited	Pharmaceutical compositions comprising rasagiline
KR101320945B1 (ko) *	2012-07-03	2013-10-23	주식회사파마킹	에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
MX2015003812A (es) *	2012-09-27	2015-07-17	Teva Pharma	Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
EP2994453A4 (en) *	2013-03-15	2017-04-12	Techfields Pharma Co., Ltd.	Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
EP2808023A1 (en) *	2013-05-30	2014-12-03	Université Pierre et Marie Curie (Paris 6)	New drug for the treatment and/or prevention of depressive disorders
CN104473942A (zh) *	2014-12-12	2015-04-01	青岛大学	一种抗帕金森氏病的药物组合物
EP3302454B1 (en)	2015-05-26	2021-03-10	Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA	Compositions for use in treating parkinson's disease and related disorders
WO2017070293A1 (en) *	2015-10-20	2017-04-27	Ironwood Pharmaceuticals, Inc.	Phosphodiesterase 9 inhibitor and levodopa therapy
US20170143681A1 (en)	2015-11-02	2017-05-25	Apkarian Technologies Llc	Methods and compositions for treating pain
CN110325214A (zh) *	2016-12-22	2019-10-11	Rvx疗法有限公司	用于预防和治疗神经元损伤的低剂量药物组合
US11253594B2 (en) *	2017-07-07	2022-02-22	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Drug combinations for protecting against neuronal cell death
JP6596483B2 (ja) *	2017-12-28	2019-10-23	テックフィールズファーマカンパニーリミテッド	パ−キンソン病治療用の新規高透過薬物及びその組成物
WO2020084168A1 (en) *	2018-10-26	2020-04-30	Icm (Institut Du Cerveau Et De La Moelle Épinière)	Tetracycline compound for treating drug-induced dyskinesia
CN113924086A (zh) *	2019-04-17	2022-01-11	维奇健康科学有限责任公司	液体药物组合物
CA3139559A1 (en) *	2019-05-09	2020-11-12	Apkarian Technologies Llc	Methods and compositions for treating pain
EP4070793A4 (en)	2019-12-06	2023-06-14	Shanghai Pharmaceuticals Holding Co., Ltd.	PHARMACEUTICAL COMPOSITION, COMPLEMENTARY KIT AND ITS APPLICATION
CN117618393A (zh)	2020-06-18	2024-03-01	凯瑞康宁生物工程（武汉）有限公司	水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en)	2020-07-24	2022-01-27	XWPharma Ltd.	Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202227131A (zh) *	2020-09-10	2022-07-16	愛爾蘭商普羅佘納生物科技有限公司	帕金森氏症之治療
WO2022076466A1 (en)	2020-10-05	2022-04-14	XWPharma Ltd.	Modified release compositions of a gamma-hydroxybutyric acid derivative
CN114762684B (zh) *	2021-01-14	2023-11-21	华益泰康药业股份有限公司	一种治疗帕金森的缓释胶囊及其制备方法
CN117098533A (zh)	2021-03-19	2023-11-21	凯瑞康宁公司	γ-羟基丁酸衍生物的组合释放型制剂的药物动力学
KR20240080457A (ko) *	2022-11-30	2024-06-07	주식회사한국파마	신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2029805T3 (es) *	1986-04-16	1992-10-01	Asta Pharma Aktiengesellschaft	Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica.
US5190763A (en) *	1990-05-07	1993-03-02	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en)	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE69532482T2 (de) *	1995-05-26	2004-11-25	Pfizer Inc.	Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
WO2001078711A2 (en)	2000-04-19	2001-10-25	Lilly Icos, Llc.	Pde-v inhibitors for treatment of parkinson's disease
US20070225379A1 (en) *	2001-08-03	2007-09-27	Carrara Dario Norberto R	Transdermal delivery of systemically active central nervous system drugs
AR044007A1 (es)	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
FR2857594B1 (fr) *	2003-07-17	2005-09-16	Servier Lab	Composition pharmaceutique pour l'administration par voie nasale de piribedil
AU2005215136A1 (en)	2004-02-20	2005-09-01	Novartis Ag	DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
EP1901721A1 (en)	2005-06-23	2008-03-26	Spherics, Inc.	Delayed release or extended-delayed release dosage forms of pramipexole
WO2007048034A2 (en)	2005-10-21	2007-04-26	Caritas St. Elizabeth Medical Center Of Boston, Inc.	Use of androgens for the treatment of parkinson' s disease
EP1970055B1 (en)	2005-12-29	2010-11-24	Osmotica Kereskedelmi És Szolgáltató Kft	Multi-layered tablet with triple release combination
CN101384545B (zh)	2006-02-17	2014-09-03	比罗利纳创新研究与发展服务药物有限公司	氘化的儿茶酚胺衍生物及包含所述化合物的药物
EP2007369A4 (en)	2006-04-03	2009-07-01	Teva Pharma	USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
DK2026803T3 (da)	2006-05-16	2012-04-16	Knopp Neurosciences Inc	Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
WO2008008398A2 (en)	2006-07-14	2008-01-17	Shionogi & Co., Ltd.	Oxime compounds and the use thereof
WO2008013860A2 (en)	2006-07-28	2008-01-31	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
EP2056818B1 (en)	2006-08-11	2011-05-25	The Johns Hopkins University	Compositions and methods for neuroprotection
AU2007288226A1 (en)	2006-08-21	2008-02-28	Prexa Pharmaceuticals, Inc.	Multimediator transporter inhibitors for use in treatment of central nervous system disorders
US7622495B2 (en)	2006-10-03	2009-11-24	Neurim Pharmaceuticals (1991) Ltd.	Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
RS52451B (en)	2006-11-01	2013-02-28	Purdue Pharma Lp	PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE
CA2684550A1 (en) *	2007-04-24	2008-10-30	Boehringer Ingelheim International Gmbh	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

2009
- 2009-06-07 PL PL09758025T patent/PL2303330T5/pl unknown
- 2009-06-07 CN CN200980129250.2A patent/CN102105169B/zh active Active
- 2009-06-07 EP EP09758025.2A patent/EP2303330B2/en active Active
- 2009-06-07 US US12/996,455 patent/US8969417B2/en active Active
- 2009-06-07 WO PCT/IL2009/000567 patent/WO2009147681A1/en active Application Filing
- 2009-06-07 HU HUE09758025A patent/HUE037974T2/hu unknown
- 2009-06-07 MX MX2010013393A patent/MX2010013393A/es active IP Right Grant
- 2009-06-07 CA CA2726833A patent/CA2726833C/en active Active
- 2009-06-07 ES ES09758025T patent/ES2659394T5/es active Active
- 2009-06-07 LT LTEP09758025.2T patent/LT2303330T/lt unknown
- 2009-06-07 BR BRPI0914902A patent/BRPI0914902B8/pt active IP Right Grant
- 2009-06-07 DK DK09758025.2T patent/DK2303330T4/da active
- 2009-06-07 KR KR1020117000189A patent/KR101613749B1/ko active Active
- 2009-06-07 AU AU2009254730A patent/AU2009254730B2/en active Active
- 2009-06-07 NZ NZ590291A patent/NZ590291A/xx not_active IP Right Cessation
- 2009-06-07 PT PT97580252T patent/PT2303330T/pt unknown
- 2009-06-07 NO NO09758025A patent/NO2303330T3/no unknown
- 2009-06-07 JP JP2011512269A patent/JP5648216B2/ja active Active
- 2009-06-07 RU RU2010154716/15A patent/RU2540470C9/ru active
2010
- 2010-12-06 CL CL2010001358A patent/CL2010001358A1/es unknown
2011
- 2011-01-03 ZA ZA2011/00034A patent/ZA201100034B/en unknown
2015
- 2015-01-22 US US14/602,518 patent/US9259418B2/en active Active - Reinstated
2018
- 2018-01-31 CY CY20181100112T patent/CY1119865T1/el unknown

Also Published As

Publication number	Publication date
PT2303330T (pt)	2018-02-12
RU2010154716A (ru)	2012-08-10
CN102105169B (zh)	2014-09-10
EP2303330B1 (en)	2017-11-15
BRPI0914902A2 (pt)	2017-06-20
AU2009254730A1 (en)	2009-12-10
CN102105169A (zh)	2011-06-22
WO2009147681A1 (en)	2009-12-10
EP2303330A1 (en)	2011-04-06
RU2540470C9 (ru)	2015-07-20
NZ590291A (en)	2013-11-29
CA2726833C (en)	2016-03-22
NO2303330T3 (pl)	2018-04-14
US20150133513A1 (en)	2015-05-14
DK2303330T4 (da)	2021-09-13
JP5648216B2 (ja)	2015-01-07
US8969417B2 (en)	2015-03-03
KR20110031181A (ko)	2011-03-24
US20110230513A1 (en)	2011-09-22
PL2303330T3 (pl)	2018-04-30
CA2726833A1 (en)	2009-12-10
MX2010013393A (es)	2011-06-21
LT2303330T (lt)	2018-04-10
ES2659394T3 (es)	2018-03-15
ES2659394T5 (es)	2021-12-13
RU2540470C2 (ru)	2015-02-10
EP2303330B2 (en)	2021-06-16
KR101613749B1 (ko)	2016-04-19
ZA201100034B (en)	2012-04-25
US9259418B2 (en)	2016-02-16
CY1119865T1 (el)	2018-06-27
JP2011522035A (ja)	2011-07-28
BRPI0914902B8 (pt)	2022-04-12
AU2009254730B2 (en)	2014-06-26
HUE037974T2 (hu)	2018-09-28
CL2010001358A1 (es)	2011-08-19
DK2303330T3 (en)	2018-02-26
BRPI0914902B1 (pt)	2022-02-22

Publication	Publication Date	Title
ZA201100034B (en)	2012-04-25	Pharmaceutical compositions for treatment of parkinson's disease
EP2151435A4 (en)	2011-09-14	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2382176A4 (en)	2015-09-09	USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL205153A0 (en)	2010-11-30	Compositions for treating parkinson's disease
IL216399A0 (en)	2012-01-31	Pharmaceutical composition for the treatment of heart diseases
IL230335A (en)	2015-07-30	A drug used to treat cartilage disease
IL208350A0 (en)	2010-12-30	Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
SG10201510665WA (en)	2016-01-28	Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
EP2187743A4 (en)	2010-10-27	FORMULATIONS FOR THE TREATMENT OF DISEASES OR EYE DISORDERS
PT2197883E (pt)	2016-02-02	Derivados de catecolamina úteis para o tratamento da doença de parkinson
EP2306824A4 (en)	2013-10-23	IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
ZA200805761B (en)	2010-03-31	Pharmaceutical composition for the treatment of nail disease
EP2320939A4 (en)	2012-09-12	TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
EP2213303A4 (en)	2011-12-28	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
ZA201009072B (en)	2012-03-28	Pharmaceutical composition for the treatment of premature ejaculation
EP2236137A4 (en)	2014-01-01	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FAT TEMPERATURE DISEASES
WO2010085799A9 (en)	2010-11-18	Compositions and method for the treatment of parkinson's disease
IL217149A0 (en)	2012-02-29	Compositions and methods for treating parkinson's disease
EP2413696A4 (en)	2012-10-24	COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2517704A4 (en)	2014-01-22	PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME
PT2344166E (pt)	2013-03-05	Composição farmacêutica para o tratamento da irritação gastrointestinal
PL2307380T3 (pl)	2013-01-31	Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
IL209804A0 (en)	2011-02-28	Pharmaceutical compositions for treatment of parkinson's disease
EP2329824A4 (en)	2013-01-16	NEW PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NOZIZEPTIVE PAIN
GB0811555D0 (en)	2008-07-30	Treatment of Alzheimer's disease